LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision, proudly based in San Diego.

We are focused on an eye drop to treat presbyopia and provide seamless vision for the vast majority of presbyopes.

In our pursuit of this better future for patients, we are excited to deliver an innovative solution to the eye care community, who has demonstrated their readiness.

Our novel lead program is an aceclidine based eye drop, with a unique MOA profile and best-in-class clinical data.

LENZ Therapeutics is committed to delivering the first and only, aceclidine-based eye drop for the treatment of presbyopia. With a unique MOA profile, aceclidine is the only pupil selective miotic.

Our groundbreaking work has the support of the investor community who sees the clear value in what we are developing. Learn more on our Pipeline page.

Our novel and lead program aims to provide an ideal pharmaceutical presbyopia solution to restore near vision, with the potential for broadest target patient population.

Presbyopia impacts 128 million people in the US.1 and research shows that adults over 50 lose on average 1.5 lines of near vision per 6 years.2
The promise of a once-daily eye drop solution is welcomed by all age groups, 45 and above. LENZ Therapeutics is looking to provide a solution to treat all eyes, all day.

At LENZ, we appreciate each other’s strengths and perspectives and we instinctively fill in the gaps. Our team is not afraid to express opinions or ask for support. We take action, and we take the time to know where we’re going.

We see speed bumps as an essential part of the ride. The LENZ team loves a challenge, and love to challenge. We encourage constructive and contagious curiosity – looking beyond the obvious.

We each rally around what we’re doing and why we’re doing it. This makes us tenacious in getting things done right. We’re unstoppable in our pursuit of better, which gives us great pride.